NOVO-B:CPH
Novo Nordisk A/S
259,60 DKK
arrow_downward
-1,46%(-3,85) 1 d.
16. okt., 17:00:00 GMT+2 · DKK
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NOVO-B…
Atvērt
261,00 DKK
Augsta
262,15 DKK
Zema
259,35 DKK
Tirgus kapitalizācija
870,08 mljrd.
Vid. apjoms
5,23 milj.
Apjoms
5,27 milj.
Augstākā 52 ned.
409,95 DKK
Zemākā 52 ned.
224,25 DKK
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
261,00 DKK
Augsta
262,15 DKK
Zema
259,35 DKK
Tirgus kapitalizācija
870,08 mljrd.
Vid. apjoms
5,23 milj.
Apjoms
5,27 milj.
Augstākā 52 ned.
409,95 DKK
Zemākā 52 ned.
224,25 DKK
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
The Motley Fool
·
pirms 6 stundām
Novo Nordisk and Eli Lilly Just Got Some Fantastic News
ad-hoc-news.de
·
pirms 7 stundām
Novo-Nordisk stock: Citi cuts target for Novo-Nordisk stock to DKK 296
Traders Union
·
pirms 15 stundām
Novo Nordisk shares technical analysis: Buyer support underpins upward price move
Foreign Policy Journal
·
pirms 21 stundas
Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount
Profils
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com